

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.373; Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • AbbVie (Adalimumab) • Bristol-Myers Squibb (Abatacept) • Pfizer (Etanercept) • Roche Products (Tocilizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Arthritis Action • Arthritis and Musculoskeletal Alliance • Arthritis Research UK • Disability Rights UK • Leonard Cheshire Disability • Muslim Council of Britain • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • Pain UK • Psoriasis and Psoriatic Arthritis Alliance • Psoriasis Association • Psoriasis Help Organisation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association of Dermatologists • British Dermatological Nursing Group • British Institute of Musculoskeletal Medicine • British Orthopaedic Association • British Skin Foundation • British Society for Rheumatology • British Society of Rehabilitation Medicine • Primary Care Dermatology Society 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Accord (methotrexate) • Amgen (adalimumab) • Biogen Idec (adalimumab, etanercept) • Concordia International (methotrexate) • Hospira (methotrexate) • Medac GmbH (methotrexate) • Morningside Healthcare (methotrexate) • Mylan (adalimumab) • Nordic Pharma (methotrexate) • Orion Pharma (methotrexate) • Pfizer (methotrexate) • Sandoz (adalimumab, etanercept, methotrexate) • Teva (methotrexate)

<ul style="list-style-type: none"> • Primary Care Rheumatology Society • Rheumatoid Arthritis Surgical Society • Physiotherapy Pain Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal Pharmaceutical Society • Royal College of Physicians • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Blackpool CCG • NHS England • NHS North Tyneside CCG • Welsh Government 	<ul style="list-style-type: none"> • Therakind (methotrexate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • British Epidermo-Epidemiology Society • Centre of Evidence-Based Dermatology, University of Nottingham • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Cochrane Skin Group • MRC Clinical Trials Unit • Orthopaedic Research UK • National Institute for Health Research • Skin Treatment and Research Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
---	---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

MTA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee